Loading
Praxis Precision Medicines, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Oct 2023.
Praxis Precision Medicines, Inc.: what insiders have been doing
Praxis Precision Medicines, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 11 insiders published 40 filings.
Only sales appear on the open market, 12 sales in all, filed by 1 insider. The totals do not cover 12 filings with an undisclosed amount.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
With 40 filings in twelve months, the company is more active than the median of 19 filings across the 5,816 companies we follow on the same exchange. Our records for Praxis Precision Medicines, Inc. go back to 2021, with 12 purchases and 20 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -303.3 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
121
Thresholds
n/a
Buy Volume
€422,210
12 ops. · all time
Sell Volume
€14M
20 ops. · all time
Who traded when
BuySaleJill DeSimone12 sales
Adage Capital Management, L.P.1 sale
Since the insiders bought
- +177.3%Entry US$22.35 · Close at T+365 US$61.97
- +124.6%Entry US$17.70 · Close at T+365 US$39.76
- +363.2%Entry US$12.78 · Close at T+365 US$59.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Praxis Precision Medicines, Inc. Strong Buy (bullish), based on 19 analysts. Average price target: US$644.42.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$239.02
Analyst consensus
19 analystsStrong buy
US$188.00Target US$644.42(+170%)US$1,201.00
Income statement
EBITDA-US$326.1M
Net income-US$303.3M0.0% margin
Valuation
PER (forward)-25.6x
P/Book5.0x
Beta2.81
Balance sheet & cash
Market capUS$6.7B
Total debtUS$110k
Free Cash Flow-US$249.1M
Debt / Equity0%
Profitability & ownership
ROE-38.9%
ROA-25.7%
% insiders0.3%
% institutions123.4%
Last declaration on 8 July 2026
Declarations121 total
20,521 shares0Common StockSEC:0001707657-26-000008:0
2,600 shares0Common StockSEC:0001707657-26-000008:1
999 sharesCommon StockSEC:0001930479-26-000003:7
8,566 sharesCommon StockSEC:0001930479-26-000003:0
3,034 sharesCommon StockSEC:0001930479-26-000003:1
10 sharesCommon StockSEC:0001930479-26-000003:2
120 sharesCommon StockSEC:0001930479-26-000003:3
320 sharesCommon StockSEC:0001930479-26-000003:4
683 sharesCommon StockSEC:0001930479-26-000003:5
1,240 sharesCommon StockSEC:0001930479-26-000003:6
1,750 sharesCommon StockSEC:0001930479-26-000003:8
2,854 sharesCommon StockSEC:0001930479-26-000003:9
1,004 sharesCommon StockSEC:0001930479-26-000003:10
504 sharesCommon StockSEC:0001930479-26-000003:11
1,279 sharesCommon StockSEC:0001930479-26-000003:12
837 sharesCommon StockSEC:0001930479-26-000003:13
11,600 shares@ US$311.32210.042% mcap99.2% of flowCommonSEC144:0001959173-26-004864
1,371 sharesCommon StockSEC:0001689548-26-000063:0
1,371 sharesCommon StockSEC:0001689548-26-000060:0
1,371 sharesCommon StockSEC:0001689548-26-000064:0
688 shares0Common StockSEC:0001689548-26-000018:0
478 shares0Common StockSEC:0001689548-26-000018:1
688 shares0Common StockSEC:0001689548-26-000017:0
943 shares@ US$275.7452.3% of flowCommon StockSEC:0001863297-26-000005:0
768 shares@ US$275.7422.5% of flowCommon StockSEC:0001827760-26-000005:0
25 of 121 declarations
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. is a U.S.-based biopharmaceutical company listed in the United States on NASDAQ, with its headquarters in Boston, Massachusetts, United States. The company was founded around the scientific work of Kiran Reddy, David Goldstein, and Steven Petrou, and its strategy is built on precision medicine for central nervous system disorders. In practice, Praxis focuses on genetically defined or biologically differentiated neurologic diseases, especially severe epilepsies and movement disorders, where targeted oral therapies may offer a meaningful clinical advantage. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1689548/000095012321003591/filename1.htm))
The company’s core engine is its proprietary Cerebrum™ platform, which has produced several clinical-stage candidates. Its lead program is ulixacaltamide, a highly selective T-type calcium channel inhibitor in development for essential tremor. Praxis says it has filed an NDA with the FDA and has already started commercial preparation and pre-launch activities, making this one of the company’s most important near-term value drivers. Relutrigine is being developed for developmental and epileptic encephalopathies (DEEs), including SCN2A-DEE and SCN8A-DEE, and Praxis has submitted an NDA for that program as well. Vormatrigine is advancing in photosensitive epilepsy, with a POWER3 trial expected in the first half of 2026. The company also has PRAX-020, in-licensed from UCB Biopharma SRL, in its portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001689548/000168954826000029/prax-20251231.htm))
Read moreShow less
From a competitive standpoint, Praxis is differentiated by its precision-CNS approach and by its focus on smaller, high-need patient subsets rather than broad primary-care markets. That can support strong scientific positioning and regulatory optionality, especially given the Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations received by some programs. At the same time, the business remains highly dependent on a limited number of pipeline assets, which is standard for a development-stage biotech but also increases execution risk. The Cerebrum platform is central to the investment case because it is designed to generate multiple first- and best-in-class oral therapies over time. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001689548/000168954826000029/prax-20251231.htm))
Geographically, operations are centered in Boston, and management has stated an intention to reach U.S. prescribers and, where appropriate, expand globally through direct commercialization or partnerships. Recent highlights include positive Phase 3 topline results for ulixacaltamide in the fourth quarter of 2025, the NDA filing for that asset, the NDA filing for relutrigine, and ongoing commercial-readiness work. For investors, PRAX remains a high-beta biotech name with meaningful event-driven upside, but also with the usual clinical, regulatory, financing, and launch-execution risks associated with late-stage CNS drug development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001689548/000168954826000029/prax-20251231.htm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
